CTMA Expands to Rheumatology


CTMA has announced that it is expanding its CT-SCOUT™ technology offering into a second therapeutic area–rheumatology. CT-SCOUT™, the company’s multi-device platform that allows health care professionals (HCP) to identify trial candidates, will now be available for sites, sponsors and contract research organizations (CROs) in three rheumatological indications: Rheumatoid Arthritis, Ankylosing Spondylarthritis and Psoriatic Rheumatism.

Read more about the announcement here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.